Melanoma cancer vaccine Seviprotimut-L, FDA Fast Track Certification

Polynoma Biopharmaceuticals incannounced that the U.SFood and DrugAdministration(
FDA) has granted fast-track designations to its melanoma cancer vaccine, Seviprotimut-L, for complementary treatment for melanoma patients with IIB/IIC phase after surgery to improve recurrence-free survivalPhoto credit: https:// The interval between the eviprotimut-l-pol-103a-polynoma-melanoma-antigen-beta-beta-phase-iii-studytbetween stage II and stage III/IV melanoma is a key therapeutic intervention point to improve patient survivalTreatment of IIB/IIC stage melanoma is mainly limited to surgery, but the disease may recur after the definitive removal of melanomaMany patients progress to a later stage after excision and progress from local stage II melanoma to local stage III, with a sharp decline in five-year survival rate (98.4% to 63.6%), and a significantly lower five-year survival rate for metastatic IV (22.5%)in the United States by 2020 In the Oncology Society (
ASCO), Polynoma announced clinical data from its Phase III study mAVIS B1, which showed improved prognosis in patients with IIB/C in the seviprotimutut-L group, benefiting from survival and good toleranceabout Seviprotimut-LSeviprotimut-L is an heterogenous, multivalent, partially purified off-the-skin melanoma antigen vaccine derived from three proprietary human melanoma cell lines Seviprotimut-L stimulates the body's bodily fluids
immunity (antibody production) and cellular immunity (killer T cells) The melanoma-related antigen (MAA) in seviprotimut-L is absorbed by antigen-present cells (e.g dendritic cells) and then activates the production of antigen-specific cytotoxic T lymphocytes (CTLs) and activates antibody responses against MAAs, which can further cause tumor cell death